Translational Medicine and Drug Discovery
Herausgeber: Littman, Bruce H.; Krishna, Rajesh
Translational Medicine and Drug Discovery
Herausgeber: Littman, Bruce H.; Krishna, Rajesh
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book focuses on the new discipline of translational medicine as it pertains to drug development within the pharmaceutical and biotechnology industry.
Andere Kunden interessierten sich auch für
- Translational Medicine and Drug Discovery164,99 €
- Bioactive Natural Products in Drug Discovery158,99 €
- Handbook of Regenerative Medicine and Tissue Engineering126,99 €
- Chemoinformatics in Drug Design and Discovery157,99 €
- Encyclopedia of Regenerative Medicine184,99 €
- Tissue Engineering and Regenerative Medicine159,99 €
- R. BrydsonElectron Energy Loss Spectroscopy130,99 €
-
-
-
This book focuses on the new discipline of translational medicine as it pertains to drug development within the pharmaceutical and biotechnology industry.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 384
- Erscheinungstermin: 20. Juni 2014
- Englisch
- Abmessung: 254mm x 178mm x 21mm
- Gewicht: 721g
- ISBN-13: 9781107435940
- ISBN-10: 1107435943
- Artikelnr.: 41639685
- Herstellerkennzeichnung
- Books on Demand GmbH
- In de Tarpen 42
- 22848 Norderstedt
- info@bod.de
- 040 53433511
- Verlag: Cambridge University Press
- Seitenzahl: 384
- Erscheinungstermin: 20. Juni 2014
- Englisch
- Abmessung: 254mm x 178mm x 21mm
- Gewicht: 721g
- ISBN-13: 9781107435940
- ISBN-10: 1107435943
- Artikelnr.: 41639685
- Herstellerkennzeichnung
- Books on Demand GmbH
- In de Tarpen 42
- 22848 Norderstedt
- info@bod.de
- 040 53433511
Part I. Translational Medicine: History, Principles and Application in Drug
Development: 1. Overview of translational medicine and drug development
Bruce H. Littman; 2. Concepts and case studies: diabetes Ann Taylor and
Roberto Calle; 3. Challenges in atherosclerosis John Millar; 4. Obesity:
new mechanisms and translational paradigms Gregory Gaich and David E.
Moller; 5. Bone disorders: case studies of translational research S. Aubrey
Stoch; 6. Case studies in neuroscience: unique challenges and examples
Gerard J. Marek; 7. Translational medicine in oncology Dominic G. Spinella;
Part II. Biomarkers and Public-Private Partnerships: 8. Biomarker
validation and application in drug development Pfizer Global Research and
Development; 9. Application of imaging methods in translational medicine
Johannes T. Tauscher and Adam Schwarz; 10. European innovative medicines
initiative Ole J. Bjerrum and Hans H. Linden; 11. Critical path institute
and the predictive safety consortium Elizabeth Gribble Walker; 12. The
biomarker consortium David B. Lee; Part III. Future Directions: 13.
Improving the quality and productivity of pharmacometric modeling and
simulation activities - the foundation for model-based drug development
Thaddeus H. Grasela, Jill Fiedler-Kelly and Robert Slusser; 14. Embracing
change: a pharmaceutical industry guide to the 21st century Mervyn Turner.
Development: 1. Overview of translational medicine and drug development
Bruce H. Littman; 2. Concepts and case studies: diabetes Ann Taylor and
Roberto Calle; 3. Challenges in atherosclerosis John Millar; 4. Obesity:
new mechanisms and translational paradigms Gregory Gaich and David E.
Moller; 5. Bone disorders: case studies of translational research S. Aubrey
Stoch; 6. Case studies in neuroscience: unique challenges and examples
Gerard J. Marek; 7. Translational medicine in oncology Dominic G. Spinella;
Part II. Biomarkers and Public-Private Partnerships: 8. Biomarker
validation and application in drug development Pfizer Global Research and
Development; 9. Application of imaging methods in translational medicine
Johannes T. Tauscher and Adam Schwarz; 10. European innovative medicines
initiative Ole J. Bjerrum and Hans H. Linden; 11. Critical path institute
and the predictive safety consortium Elizabeth Gribble Walker; 12. The
biomarker consortium David B. Lee; Part III. Future Directions: 13.
Improving the quality and productivity of pharmacometric modeling and
simulation activities - the foundation for model-based drug development
Thaddeus H. Grasela, Jill Fiedler-Kelly and Robert Slusser; 14. Embracing
change: a pharmaceutical industry guide to the 21st century Mervyn Turner.
Part I. Translational Medicine: History, Principles and Application in Drug
Development: 1. Overview of translational medicine and drug development
Bruce H. Littman; 2. Concepts and case studies: diabetes Ann Taylor and
Roberto Calle; 3. Challenges in atherosclerosis John Millar; 4. Obesity:
new mechanisms and translational paradigms Gregory Gaich and David E.
Moller; 5. Bone disorders: case studies of translational research S. Aubrey
Stoch; 6. Case studies in neuroscience: unique challenges and examples
Gerard J. Marek; 7. Translational medicine in oncology Dominic G. Spinella;
Part II. Biomarkers and Public-Private Partnerships: 8. Biomarker
validation and application in drug development Pfizer Global Research and
Development; 9. Application of imaging methods in translational medicine
Johannes T. Tauscher and Adam Schwarz; 10. European innovative medicines
initiative Ole J. Bjerrum and Hans H. Linden; 11. Critical path institute
and the predictive safety consortium Elizabeth Gribble Walker; 12. The
biomarker consortium David B. Lee; Part III. Future Directions: 13.
Improving the quality and productivity of pharmacometric modeling and
simulation activities - the foundation for model-based drug development
Thaddeus H. Grasela, Jill Fiedler-Kelly and Robert Slusser; 14. Embracing
change: a pharmaceutical industry guide to the 21st century Mervyn Turner.
Development: 1. Overview of translational medicine and drug development
Bruce H. Littman; 2. Concepts and case studies: diabetes Ann Taylor and
Roberto Calle; 3. Challenges in atherosclerosis John Millar; 4. Obesity:
new mechanisms and translational paradigms Gregory Gaich and David E.
Moller; 5. Bone disorders: case studies of translational research S. Aubrey
Stoch; 6. Case studies in neuroscience: unique challenges and examples
Gerard J. Marek; 7. Translational medicine in oncology Dominic G. Spinella;
Part II. Biomarkers and Public-Private Partnerships: 8. Biomarker
validation and application in drug development Pfizer Global Research and
Development; 9. Application of imaging methods in translational medicine
Johannes T. Tauscher and Adam Schwarz; 10. European innovative medicines
initiative Ole J. Bjerrum and Hans H. Linden; 11. Critical path institute
and the predictive safety consortium Elizabeth Gribble Walker; 12. The
biomarker consortium David B. Lee; Part III. Future Directions: 13.
Improving the quality and productivity of pharmacometric modeling and
simulation activities - the foundation for model-based drug development
Thaddeus H. Grasela, Jill Fiedler-Kelly and Robert Slusser; 14. Embracing
change: a pharmaceutical industry guide to the 21st century Mervyn Turner.